CTD Holdings' European Clinical Trial Adopted by National Institute for Health Research of England

ALACHUA, FL--(Marketwired - January 16, 2018) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company's Phase I/II Clinical Trial "A Phase I/II Study to Evaluate the Safety and pK of IV Trappsol® Cyclotm (HPBCD) in Patients with Niemann-Pick Disease Type C (NPC-1) and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes" (NCT02912793) has been adopted by the National Institute for Health Research's Clinical Research Network (CRN) of England. The CRN makes it possible for patients and health professionals across England to participate in clinical research studies throughout the National Health Service (NHS).

"We are excited and proud to be included in the work of the CRN as it advances clinical trials to benefit patients in England," said CTD Chairman and CEO N. Scott Fine. "CRN support is another means through which we can complete our study swiftly."

CRN meets the costs of NHS staff that support research; provides specialist training so that patients can be confident that research is being delivered by experienced front-line staff; meets the costs of using NHS facilities and equipment needed in the course of studies; and, provides practical help in identifying and recruiting patients however needed.

CTD supports two sites in England: Salford Royal Foundation NHS Trust under the leadership of Dr. Reena Sharma, and University College London Hospitals NHS Foundation Trust under the leadership of Dr. Robin Lachmann.

About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclotm, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease, on a compassionate use basis as well as in formal clinical trials. Additional indications for the active ingredient in Trappsol® Cyclotm, are in development. For additional information, visit the company's website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.